NCT01255462View on ClinicalTrials.gov

Intravitreal LFG316 in Patients With Advanced Age-related Macular Degeneration

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 30, 2010

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Advanced Age-related Macular Degeneration
Interventions
BIOLOGICAL

LFG316

BIOLOGICAL

LFG316

BIOLOGICAL

LFG316

BIOLOGICAL

LFG316

Trial Locations (8)

28210

Charlotte Eye, Ear, Nose and Throat Associates, Charlotte

33880

Center for Retina and Macular Disease, Winter Haven

33912

National Ophthalmic Research Institute, Fort Myers

75231

Texas Retina Associates, Dallas

77030

Retina Consultants of Houston, Houston

85014

Retinal Consultants of Arizona,, Phoenix

90211

Retina-Vitreous Associates Medical Group,, Beverly Hills

02114

Opthalmic Consultants of Boston, Boston

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY